Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to
prevent progression to AIDS in people living with HIV-1. However, owing to the persistence …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Abstract HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV)
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …

Toll-like receptors (TLRs) are an evolutionarily conserved family in the innate immune
system and are the first line of host defense against microbial pathogens by recognizing …

Antiretroviral therapy inhibits HIV-1 replication but is not curative due to establishment of a
persistent reservoir after virus integration into the host genome. Reservoir reduction is …

Globally, the majority of people living with HIV are women or girls, but they have been a
minority of participants in clinical trials and observational studies of HIV. Despite this …

BACKGROUND Identifying factors that predict the timing of HIV rebound after treatment
interruption will be crucial for designing and evaluating interventions for HIV remission …

Toll-like receptors (TLRs), as a family of pattern recognition receptors, play an important role
in the recognition of HIV-1 molecular structures by various cells of the innate immune …

Successful approaches for eradication or cure of HIV-1 infection are likely to include
immunological mechanisms, but remarkably little is known about how human immune …